FDA Grants Priority Review for Merck's Cancer Drug Ifinatamab Deruxtecan

The U.S. Food and Drug Administration has accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan. This application seeks approval for the treatment of adult patients with extensive stage small cell lung cancer who have undergone at least one prior systemic therapy.

Ifinatamab deruxtecan, co-developed by Merck and Daiichi Sankyo, has the potential to be the first therapy targeting B7-H3 in this specific patient population. The Priority Review designation is significant as it may expedite the approval process, allowing for quicker access to this innovative treatment for patients in need.

Investors in Merck, listed on the New York Stock Exchange under the ticker MRK, are closely monitoring this development, as it underscores the company's growth potential in the oncology sector. The outcome of the review could have substantial implications for both patient care and Merck's market position.

© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Source: KLEA News